Evidence map›Paper›PMID 21791467›Full record

Trial reportHaematologica2011

The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.

Sarolta Nahajevszky, Hajnalka Andrikovics, Arpad Batai, Emma Adam, Andras Bors, Judit Csomor, Laszlo Gopcsa, Magdalena Koszarska, Andras Kozma, Nora Lovas and 9 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. The Contribution ofInternational journal of molecular sciences · 2022
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Inherited predisposition to myeloproliferative neoplasms.Therapeutic advances in hematology · 2013
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Sarolta NahajevszkyDepartment of Hematology and Stem Cell Transplantation, St Istvan and St Laszlo Hospital, Budapest, Hungary. nahajevszky@gmail.com
Hajnalka Andrikovics
Arpad Batai
Emma Adam
Andras Bors
Judit Csomor
Laszlo Gopcsa
Magdalena Koszarska
Andras Kozma
Nora Lovas
Sandor Lueff
Zoltan Matrai
Nora Meggyesi
Janos Sinko
Andrea Sipos
Andrea Varkonyi
Sandor Fekete
Attila Tordai
Tamas Masszi
Unified Szent István and Szent László Hospital · HUHungarian National Blood Transfusion Service · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrognostic risk stratification according to acquired or inherited genetic alterations has received increasing attention in acute myeloid leukemia in recent years. A germline Janus kinase 2 haplotype designated as the 46/1 haplotype has been reported to be associated with an inherited predisposition to myeloproliferative neoplasms, and also to acute myeloid leukemia with normal karyotype. The aim of this study was to assess the prognostic impact of the 46/1 haplotype on disease characteristics and treatment outcome in acute myeloid leukemia. DESIGN AND

methodsJanus kinase 2 rs12343867 single nucleotide polymorphism tagging the 46/1 haplotype was genotyped by LightCycler technology applying melting curve analysis with the hybridization probe detection format in 176 patients with acute myeloid leukemia under 60 years diagnosed consecutively and treated with curative intent.

resultsThe morphological subtype of acute myeloid leukemia with maturation was less frequent among 46/1 carriers than among non-carriers (5.6% versus 17.2%, P = 0.018, cytogenetically normal subgroup: 4.3% versus 20.6%, P = 0.031), while the morphological distribution shifted towards the myelomonocytoid form in 46/1 haplotype carriers (28.1% versus 14.9%, P = 0.044, cytogenetically normal subgroup: 34.0% versus 11.8%, P = 0.035). In cytogenetically normal cases of acute myeloid leukemia, the 46/1 carriers had a considerably lower remission rate (78.7% versus 94.1%, P = 0.064) and more deaths in remission or in aplasia caused by infections (46.8% versus 23.5%, P = 0.038), resulting in the 46/1 carriers having shorter disease-free survival and overall survival compared to the 46/1 non-carriers. In multivariate analysis, the 46/1 haplotype was an independent adverse prognostic factor for disease-free survival (P = 0.024) and overall survival (P = 0.024) in patients with a normal karyotype. Janus kinase 2 46/1 haplotype had no impact on prognosis in the subgroup with abnormal karyotype.

conclusionsJanus kinase 2 46/1 haplotype influences morphological distribution, increasing the predisposition towards an acute myelomonocytoid form. It may be a novel, independent unfavorable risk factor in acute myeloid leukemia with a normal karyotype.

Indexed as

Germ-Line MutationPolymorphism, Single NucleotideAdolescentAdultDisease-Free SurvivalFemaleFollow-Up StudiesHaplotypesHumansJanus Kinase 2KaryotypeLeukemia, Myeloid, AcuteMaleMiddle AgedRisk FactorsSurvival RateJAK2 protein, humanJanus Kinase 2

Identifiers

PMID21791467
PMCPMC3208678
OpenAlexW2022425092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.